Completed

A Comparative Open Labeled Clinical Study to Evaluate the Efficacy and Tolerability of Two Different Intravaginal Formulations Containing a Combination of Clindamycin and Clotrimazole in Vaginal Infections

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

ClinSupV3 -soft gelatin capsule

+ ClinSupV3ER- Extended release tablet

Drug
Who is being recruted

Urogenital Diseases+13

+ Genital Diseases

+ Bacterial Infections and Mycoses

From 18 to 65 Years
+18 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 4
Interventional
Study Start: April 2011
See protocol details

Summary

Principal SponsorDr Bharti Daswani
Last updated: October 2, 2012
Sourced from a government-validated database.Claim as a partner

Study start date: April 1, 2011

Actual date on which the first participant was enrolled.

This is a Randomized, Comparative, Prospective, Open label, Single center study to compare the 3 day treatment course of intravaginal soft gelatin capsule containing clindamycin and clotrimazole versus intravaginal ER tablets of clindamycin and clotrimazole in patients with vaginal discharge and clinical diagnosis of bacterial, trichomonal, candidal or mixed vaginitis with respect to efficacy and tolerability; and to study the in vitro drug release pattern of intravaginal soft gelatin capsule and intravaginal ER tablets containing clindamycin and clotrimazole. The study will be conducted in B.J. Medical College & Sassoon General Hospitals, Pune. The study will be completed in 60 patients [30 patients in each group]. The primary outcome measure is absence of any clinical sign suggestive of infective vaginitis and a vaginal swab that is negative for bacterial, trichomonal or candidal vaginitis at 8th day after start of treatment [Effectiveness in inducing a remission]. The secondary outcome measures will be absence of any clinical sign suggestive of infective vaginitis and a vaginal swab that is negative for bacterial, trichomonal or candidal vaginitis at 29th day after start of treatment [Effectiveness in maintaining a remission] and ability to complete the 3day course without any break or experiencing intolerable side effects [Tolerability].

NCT01697826
Principal SponsorDr Bharti Daswani
Last updated: October 2, 2012
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

73 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Female

Biological sex of participants that are eligible to enroll.

From 18 to 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesGenital DiseasesBacterial Infections and MycosesBacterial InfectionsFemale Urogenital Diseases and Pregnancy ComplicationsGenital Diseases, FemaleInfectionsMycosesParasitic DiseasesProtozoan InfectionsVaginal DiseasesFemale Urogenital DiseasesCandidiasisTrichomonas InfectionsVaginitisVaginosis, Bacterial

Criteria

5 inclusion criteria required to participate
Age at least 18 years

Agree not to douche or use any intravaginal products during the study period (including tampons, medications and devices)

Agree to no intercourse for 8 days from the day of start of treatment

Capable of giving written informed consent

Show More Criteria

13 exclusion criteria prevent from participating
Any antifungal or antibiotic use 14 days prior to enrolment

History of hypersensitivity to clotrimazole, clindamycin or lincomycin

History of regional enteritis, ulcerative colitis or antibiotic associated colitis

Immunosuppressive drug within 4 months

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Active Comparator
Soft gelatin capsule containing 100mg Clindamycin and 200mg clotrimazole administered per vaginally for 3 consecutive days

Group II

Active Comparator
ER tablets containing 100mg clindamycin and 200mg clotrimazole administered per vaginally for 3 consecutive days.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

BJ Govt. Medical College & Sassoon General Hospitals, Pune

Pune, IndiaOpen BJ Govt. Medical College & Sassoon General Hospitals, Pune in Google Maps
CompletedOne Study Center